ArticleRSC advances2018
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens.
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- N-terminal lipidation enhances membrane interaction and antifungal activity of a Trematocine-derived decapeptide.Applied microbiology and biotechnology · 2026Article
- Antarctic Fish Antimicrobial Peptides Active Against Bacterial and Viral Pathogens of Aquacultural Importance.Antibiotics (Basel, Switzerland) · 2026Article
- Anticancer Activity of the Antimicrobial Myristoylated Peptide Myr-B in HeLa Cells: Cytotoxic, Membrane-Disruptive and Proteomic Insights.International journal of molecular sciences · 2026Article
- Antibiofilm activity of a chionodracine-derived peptide by NMR-based metabolomics of cell-free supernatant of Acinetobacter baumannii clinical strains.FEBS open bio · 2026Article
- Structure-Activity Relationship and Biosafety of Linear Pentapeptide Analogs Derived from Battacin for Antimicrobial Development.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Anti-Virulence Potential of a Chionodracine-Derived Peptide against Multidrug-ResistantInternational journal of molecular sciences · 2022Article
- Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective againstInternational journal of molecular sciences · 2022Article
- COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?Frontiers in microbiology · 2022Review
- Attacins: A Promising Class of Insect Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2021Review
- Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.International journal of molecular sciences · 2020Review
- Structural Analysis and Design of Chionodracine-Derived Peptides Using Circular Dichroism and Molecular Dynamics Simulations.International journal of molecular sciences · 2020Article
- Trematocine, a Novel Antimicrobial Peptide from the Antarctic FishAntibiotics (Basel, Switzerland) · 2020Article
- Intrinsically disordered HAX-1 regulates CaBiochimica et biophysica acta. Biomembranes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Starting from the sequence of the amphipathic α-helix of chionodracine (Cnd, 22 amino acids), we designed a series of mutants to increase Cnd's antimicrobial activity and selectivity toward prokaryotic cells and drug-resistant bacterial pathogens. We characterized these new Cnd-derived peptides using fluorescence, CD spectroscopy, and transmission electron microscopy, studying their interactions with synthetic lipid vesicles and assaying their biological function against
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.